Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 391 participants.
Also called NCT01169779
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 391 participants
- Sponsor
- Registry
-
NCT01169779
-
- Main results
- Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Hong Kong SAR China, Malaysia, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT01169779. Randomized; double masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2011-12 (actual). Results posted on 2016-10-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
- Acronym
- GetGoal-M-Asia
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Lixisenatide (AVE0010)
- Intervention (Drug)
- Placebo
- Intervention (Device)
- Pen auto-injector
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Sulfonylurea
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01169779- Content hash
f3dc2b609ab9b6105c5ae82d6b057ad206caefe7e4679918f7f36f0ebb7e1ed2